2cureX AB

Equities

2CUREX

SE0010468124

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 06:25:32 2024-04-29 am EDT			5-day change	1st Jan Change
0.364 ^SEK	-18.39%		-7.85%	-81.89%

Feb. 29	2curex AB Elects Grith Hagel as a New Board Member	CI
Feb. 22	2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

2cureX AB Announces Executive Changes, Effective 1 January 2024

December 29, 2023 at 08:30 am EST

The Board of Directors of 2cureX AB (publ) announced changes to the management: Effective 1 January 2024, CSO Ole Thastrup will be leaving his CSO position to become Vice- Chairman of the Board of Directors.

Latest news about 2cureX AB

2curex AB Elects Grith Hagel as a New Board Member	Feb. 29	CI
2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
2cureX AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
2cureX AB Announces Change to the Board of Directors	Jan. 04	CI
2cureX AB Announces CEO Changes	Dec. 29	CI
2cureX AB Announces Executive Changes, Effective 1 January 2024	Dec. 29	CI
2cureX Makes Executive Changes Amid Planned Global Expansion of IndiTreat Tests; Shares Drop	Dec. 29	MT
2cureX AB Receives Ethical Approval for HIPEC Clinical Trial	Dec. 06	CI
2cureX AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
2Curex AB Appoints Tonni Bülow-Nielsen as Board Member and Chairman	Nov. 14	CI
Transcript : 2cureX AB, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
2cureX Announces to Focus All Resources on Making IndiTreat Testing Available at Hospitals Worldwide by Accelerating the Development of an Automated IVD System	23-10-26	CI
2cureX Signs Contract with Notified Body in EU for Certification of Cancer Tests	23-10-11	MT
2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation	23-08-30	CI
Transcript : 2cureX AB, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
2cureX AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Transcript : 2cureX AB - Special Call	23-07-12
2cureX AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
2cureX AB Provides Sales Guidance for Second Quarter	23-04-12	CI
Transcript : 2cureX AB, Q1 2023 Guidance/Update Call, Apr 12, 2023	23-04-12
2cureX Receives Grant from the Innovation Fund Denmark to Support Clinical Development of a Novel IndiTreat Product	23-04-12	CI
2cureX Announces Launch of Updated Specimen Collection Set	23-03-23	CI
Transcript : 2cureX AB, Q4 2022 Earnings Call, Feb 24, 2023	23-02-24
2cureX AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI

Chart 2cureX AB

Duration

Period

More charts

Company Profile

2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
2CUREX AB	-81.89%	716K
EXACT SCIENCES CORPORATION	-20.55%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+47.97%	3.25B
GUARDANT HEALTH, INC.	-32.75%	2.11B
BGI GENOMICS CO., LTD.	-14.15%	2.08B
VERACYTE, INC.	-26.06%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+19.85%	1.02B
SEEGENE, INC.	-2.62%	733M
CAREDX, INC	-31.67%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.88%	383M

Bio Diagnostics & Testing